Circulating angiopoietin-like protein 3 levels and subsequent cardiovascular outcomes in patients with coronary artery disease
An increased risk of cardiovascular events was observed in patients with CAD who exhibited ANGPTL3> 363.4 ng/mL, and the findings suggest circulating ANGPTL3 as a potential therapeutic target to further mitigate subsequent cardiovascular events’ risks in patients with CAD.